A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation.
JHEP Rep
; 3(4): 100291, 2021 Aug.
Article
em En
| MEDLINE
| ID: mdl-34169246
ACLF, acute-on-chronic liver failure; AD, acute decompensation of liver cirrhosis; AE, adverse event; AESI, AE of special interest; ATMP, advanced therapy medicinal product; Alcoholic liver disease; BW, body weight; CRP, C-reactive protein; EASL-CLIF, European Association for the Study of Chronic Liver Failure; HALPC, human allogeneic liver-derived progenitor cells; INR, international normalised ratio; Liver regenerative medicine; MELD, model for end-stage liver disease; MSC, mesenchymal stem cells; SAE, serious AE; SAS, safety analysis set; SUSAR, suspected unexpected serious adverse reaction; Stem cell; TEG, thromboelastography; TGT, thrombin generation test; i.v., intravenous
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
JHEP Rep
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Bélgica